Artivion (NYSE:AORT) Stock Price Up 5.7% – Still a Buy?

Shares of Artivion, Inc. (NYSE:AORT) rose 5.7% during mid-day trading on Tuesday . The stock traded as high as $29.35 and last traded at $29.94. 91,970 shares traded hands during trading, a decline of 84% from the average session volume of 592,308 shares. The stock had previously closed at $28.32.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Canaccord Genuity Group upped their price objective on Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research note on Monday, June 1st. Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 target price on shares of Artivion in a research note on Monday, July 20th. Finally, Citizens Jmp lowered their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $44.83.

Artivion Trading Down 0.0%

The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. The firm has a 50-day moving average price of $24.77 and a 200-day moving average price of $30.24. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -412.77 and a beta of 1.25.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The business had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. As a group, sell-side analysts predict that Artivion, Inc. will post 0.45 EPS for the current year.

Insider Activity at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the sale, the senior vice president owned 60,259 shares in the company, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jean F. Holloway sold 977 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the sale, the senior vice president directly owned 184,118 shares of the company’s stock, valued at approximately $5,245,521.82. This represents a 0.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 6.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Artivion

Several hedge funds have recently modified their holdings of the stock. Verition Fund Management LLC increased its stake in Artivion by 1.6% in the 3rd quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock worth $716,000 after purchasing an additional 274 shares in the last quarter. Entropy Technologies LP lifted its stake in Artivion by 6.0% during the fourth quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock valued at $251,000 after buying an additional 310 shares in the last quarter. Rockefeller Capital Management L.P. boosted its holdings in shares of Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after buying an additional 399 shares during the period. Arizona State Retirement System increased its position in shares of Artivion by 4.6% in the fourth quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock worth $512,000 after acquiring an additional 494 shares in the last quarter. Finally, Amundi raised its holdings in shares of Artivion by 7.5% during the first quarter. Amundi now owns 7,186 shares of the company’s stock valued at $263,000 after acquiring an additional 501 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.